United States FDA Clears Mesoblast Limited (ASX:MSB) Phase 2 Trial For Cervical Spinal Fusion

  Melbourne, Australia, May 19, 2010 - (ABN Newswire) - Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB) (ADR:MBLTY), today announced that it has received clearance from the United States Food and Drug Administration (FDA) to begin Phase 2 clinical trials of its & quot;off-the-shelf & quot; or allogeneic stem cell product NeoFuse(TM) for fusion of the cervical spine in the neck.  

Sydney

  [ Change ]
 
Today

Rain.
Tomorrow

Min: 15°
Max: 15°
Rain easing.
 

Account

Login

To access your account and listings



Remember me
   
   
   
 
 
Find Hunter Valley accommodation online